Home > News > Majority Investment Made in New Nanotech Subsidiary
April 22nd, 2004
Majority Investment Made in New Nanotech Subsidiary
Arrowhead Research Corporation, an emerging company in the field of nanotechnology, announced today that it has agreed to take a majority position in Insert Therapeutics, Inc., a Pasadena-based company focused on designing, developing and commercializing delivery-enhanced therapeutics using its patented class of polymers.
Pixelligent Closes $5.5 Million in Funding: Capital Will Be Used to Support Global Customer Growth December 12th, 2014
Nanometrics Announces Upcoming Investor Events November 19th, 2014
Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014
Arrowhead to Present at Upcoming Conferences November 15th, 2014